Safety of Romiplostim Administered Immediately after Cord-Blood Transplantation: A Phase I Trial

This Phase I dose-escalation study included six adults with hematologic malignancies in remission. Romiplostim was administered subcutaneously within seven days after single-unit cord-blood transplantation, initially at doses of 5 µg/kg or 10 µg/kg in three patients, then once a week for 14 weeks or until platelet recovery.